logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11574747 B1

PDFFull Text
Date of Patent:
Feb. 07, 2023

Filed:

Apr. 20, 2018

Methods of treating cancer with placenta growth factor peptide linked to immunotherapeutic antibodies

Applicant:

The University of Chicago, Chicago, IL (US);

Inventors:

Jeffrey A. Hubbell, Chicago, IL (US);

Jun Ishihara, Chicago, IL (US);

Ako Ishihara, Chicago, IL (US);

Kazuto Fukunaga, Chicago, IL (US);

Melody Swartz, Chicago, IL (US);

Assignee:

The University of Chicago, Chicago, IL (US);

Attorney:

Norton Rose Fulbright US LLP

Primary Examiner:

Elly-Gerald Stoica

Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 38/18 (2006.01); A61K 39/395 (2006.01); C07K 14/475 (2006.01); A61K 39/00 (2006.01); G21F 5/12 (2006.01); G21F 7/005 (2006.01); A61K 38/19 (2006.01); A61K 38/36 (2006.01); A61K 45/06 (2006.01); C07K 14/52 (2006.01); C07K 14/755 (2006.01); C07K 16/28 (2006.01); G21F 5/14 (2006.01);
U.S. Cl.
CPC ...
G21F 5/12 (2013.01); A61K 9/0019 (2013.01); A61K 38/18 (2013.01); A61K 38/195 (2013.01); A61K 38/36 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/475 (2013.01); C07K 14/522 (2013.01); C07K 14/755 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2878 (2013.01); G21F 7/005 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C07K 2319/70 (2013.01); G21F 5/14 (2013.01);
Abstract

The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with an antibody that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.

Find Patent Forward Citations

Loading…